S3 E4: Discern's Christine Juday on Value-Based Insurance Design

Redeeming Value

Content provided by W2O Group. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by W2O Group or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

2+ y ago 15:10

MP3•Episode home

Archived series ("Inactive feed" status)

When? This feed was archived on May 30, 2023 00:27 (11M ago). Last successful fetch was on April 25, 2023 10:11 (12M ago)

Why? Inactive feed status. Our servers were unable to retrieve a valid podcast feed for a sustained period.

What now? You might be able to find a more up-to-date version using the search function. This series will no longer be checked for updates. If you believe this to be in error, please check if the publisher's feed link below is valid and contact support to request the feed be restored or if you have any other concerns about this.

Value-based insurance design (VBID) uses incentives to increase health care quality and to promote cost efficient health care services and consumer choices. But like all approaches to health care cost containment, VBID isn’t one-size-fits-all. For VBID to be effective—that is, promote high-quality services and discourage use of low-quality care—incentives must embrace clinical nuance, using data to assess how clinical benefits vary by person, provide and site of service.

Leslie shifts from our typical “supply side” perspective to talk health care demand and how VBID engages consumers in their own health decisions with Christine Juday, Vice President at Discern Health, Real Chemistry’s consultancy focused on quality-based payment and delivery models.

For more news about VBID and other value-based delivery models, sign up for Real Chemistry’s Quality Report newsletter. LINK: https://www.w2ogroup.com/quality-report-newsletter/

16 episodes

#Business News #Medicine #Access #Biotechnology #Drugpricing #Healthcare #Healtheconomics #Healthinsurance #Healthpolicy #Medical #Pbms #Pharmaceutical #Reimbursement #Value #Fitness #News #W2O Groups #Health and Well-Being